INCY:NSD-Incyte Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 79.63

Change

+0.97 (+1.23)%

Market Cap

USD 17.29B

Volume

0.79M

Average Target Price

USD 93.63 (+17.58%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-01 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+2.59 (+1.67%)

USD61.26B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-2.17 (-1.02%)

USD55.25B 20.66 15.08
REGN Regeneron Pharmaceuticals, Inc

+12.48 (+2.77%)

USD48.27B 14.76 11.55
ALXN Alexion Pharmaceuticals, Inc

-0.78 (-0.51%)

USD33.58B 56.16 33.22
BGNE BeiGene, Ltd

-0.61 (-0.19%)

USD29.06B N/A N/A
RPRX Royalty Pharma plc

+1.46 (+3.14%)

USD28.27B 22.60 14.17
SGEN Seagen Inc

+1.44 (+0.95%)

USD27.38B 44.84 41.48
BNTX BioNTech SE

+1.18 (+1.08%)

USD26.25B -99,999.99 N/A
GMAB Genmab A/S

+1.25 (+3.69%)

USD22.15B 26.59 3.17
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing INCY

Symbol Name Weight Mer Price(Change) Market Cap
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

-0.65 (-3.05%)

USD9.34M
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
DWSH AdvisorShares Dorsey Wrig.. 0.00 % 3.67 %

-0.12 (-1.21%)

USD0.04B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.12 (+2.10%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.45% 15% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.45% 15% F 9% F
Trailing 12 Months  
Capital Gain 0.72% 31% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.72% 31% F 22% F
Trailing 5 Years  
Capital Gain 8.19% 50% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.19% 50% F 26% F
Average Annual (5 Year Horizon)  
Capital Gain 6.66% 48% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.66% 47% F 54% F
Risk Return Profile  
Volatility (Standard Deviation) 36.01% 76% C 41% F
Risk Adjusted Return 18.50% 51% F 45% F
Market Capitalization 17.29B 98% A+ 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 47.64 19% F 24% F
Price/Book Ratio 6.65 44% F 29% F
Price / Cash Flow Ratio -138.79 96% A 95% A
EV/EBITDA 35.20 20% F 27% F
Management Effectiveness  
Return on Equity -11.35% 89% B+ 41% F
Return on Invested Capital -12.47% 82% B- 32% F
Return on Assets -4.32% 90% A- 35% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.34 37% F 27% F
Short Percent 2.70% 77% C+ 54% F
Beta 0.79 78% C+ 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector